Dermata Therapeutics (DRMA) Price & Analysis

Compare

125 Followers

DRMA Stock Chart & Stats

Day’s Range― - ―

52-Week Range$5.09 - $24.90

Previous CloseN/A

Volume28.34K

Average Volume (3M)25.41K

Market Cap

$3.94M

Enterprise Value-$475.87K

Total Cash (Recent Filing)$6.48M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta1.19

Next Earnings

Nov 18, 2025

EPS Estimate

-1.59

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.66

Shares Outstanding681,557

10 Day Avg. Volume22,933

30 Day Avg. Volume25,414

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap-0.12

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda0.05

Forecast

1Y Price Target

$10.00

Price Target Upside69.49% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Bulls Say, Bears Say

Bulls Say

Clinical TrialsPositive topline results from the first pivotal Phase 3 trial of XYNGARI demonstrate highly statistically significant and clinically meaningful improvement in acne.

Product InnovationXYNGARI is the first once-weekly topical product candidate to demonstrate clinical benefit in a Phase 3 trial, potentially improving patient compliance compared to FDA-approved topicals requiring daily application.

Bears Say

Capital NeedsThe company is pre-revenue and a capital raise will likely be required before the end of the year.

Share DilutionExpected share dilution from anticipated capital raises to support clinical initiatives has led to a lowered 12-month price target to $10.00.

Dermata Therapeutics News

Dermata Therapeutics price target lowered to $10 from $30 at Maxim

Maxim lowered the firm’s price target on Dermata Therapeutics (DRMA) to $10 from $30 and keeps a Buy...

14d ago

DRMA

Dermata Therapeutics Regains Nasdaq Compliance by August 2025

The latest announcement is out from Dermata Therapeutics ( ($DRMA) ). On May 14, 2025, Dermata Therapeutics received...

10d ago

DRMA

Dermata Therapeutics Reports Positive Phase 3 Trial Results

An announcement from Dermata Therapeutics ( ($DRMA) ) is now available. Dermata Therapeutics announced positive results from its...

22d ago

DRMA

Dermata Therapeutics Inc trading halted, news pending

19:50 EDT Dermata Therapeutics (DRMA) Inc trading halted, news pending Published first on TheFly – the ultimate source...

1M ago

DRMA

Dermata Therapeutics Announces Reverse Stock Split

The latest update is out from Dermata Therapeutics ( ($DRMA) ). On July 30, 2025, Dermata Therapeutics announced...

1M ago

DRMA

Dermata Therapeutics Holds Annual Stockholders Meeting

The latest announcement is out from Dermata Therapeutics ( ($DRMA) ). On July 15, 2025, Dermata Therapeutics held...

2M ago

DRMA

Dermata Therapeutics receives notice of grant of Australian patent

Dermata Therapeutics (DRMA) announced the Australian Patent Office has granted its patent application for its DMT410 program for...

2M ago

DRMA

Dermata Faces Nasdaq Delisting Risk, Plans Stock Split

Dermata Therapeutics ( ($DRMA) ) has issued an announcement. On May 14, 2025, Dermata Therapeutics received a letter...

2M ago

DRMA

Dermata Therapeutics Begins Manufacturing for STAR-2 Trial

Dermata Therapeutics ( ($DRMA) ) has provided an update. On May 20, 2025, Dermata Therapeutics announced the initiation...

4M ago

DRMA

Dermata Therapeutics price target lowered to $3 from $6 at Maxim

Maxim analyst Anthony Vendetti lowered the firm’s price target on Dermata Therapeutics (DRMA) to $3 from $6 and...

4M ago

DRMA

Dermata Faces Nasdaq Delisting Risk Over Bid Price

Dermata Therapeutics ( ($DRMA) ) has shared an announcement. On May 14, 2025, Dermata Therapeutics, Inc. announced that...

4M ago

DRMA

Dermata Reports Positive Phase 3 Trial Results

Dermata Therapeutics ( ($DRMA) ) just unveiled an update. In the first quarter of 2025, Dermata Therapeutics announced...

4M ago

DRMA

Dermata Therapeutics reports Q1 EPS (45c) vs. ($7.06) last year

“It was an exciting quarter for our team to announce positive topline results of the XYNGARI Phase 3...

4M ago

DRMA

Dermata Therapeutics sees cash runway into 1Q26

As of March 31, 2025, the Company had $9.7 million in cash and cash equivalents, compared to $3.2...

4M ago

DRMA

DRMA FAQ

What was Dermata Therapeutics’s price range in the past 12 months?

Dermata Therapeutics lowest stock price was $5.09 and its highest was $24.90 in the past 12 months.

What is Dermata Therapeutics’s market cap?

Dermata Therapeutics’s market cap is $3.94M.

When is Dermata Therapeutics’s upcoming earnings report date?

Dermata Therapeutics’s upcoming earnings report date is Nov 18, 2025 which is in 75 days.

How were Dermata Therapeutics’s earnings last quarter?

Dermata Therapeutics released its earnings results on Aug 13, 2025. The company reported -$1.66 earnings per share for the quarter, beating the consensus estimate of -$2.9 by $1.24.

Is Dermata Therapeutics overvalued?

According to Wall Street analysts Dermata Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Dermata Therapeutics pay dividends?

Dermata Therapeutics does not currently pay dividends.

What is Dermata Therapeutics’s EPS estimate?

Dermata Therapeutics’s EPS estimate is -1.59.

How many shares outstanding does Dermata Therapeutics have?

Dermata Therapeutics has 681,557 shares outstanding.

What happened to Dermata Therapeutics’s price movement after its last earnings report?

Dermata Therapeutics reported an EPS of -$1.66 in its last earnings report, beating expectations of -$2.9. Following the earnings report the stock price went down -9.783%.

Which hedge fund is a major shareholder of Dermata Therapeutics?

Currently, no hedge funds are holding shares in DRMA

Dermata Therapeutics Stock Smart Score

Underperform

Fundamentals

Return on Equity

-231.27%

Trailing 12-Months

Asset Growth

26.81%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Dermata Therapeutics

Dermata Therapeutics, Inc. (DRMA) is a clinical-stage biotechnology company focused on developing and commercializing innovative pharmaceutical products for the treatment of medical and aesthetic skin conditions. The company operates in the biotechnology and pharmaceuticals sectors, leveraging its unique Spongilla technology platform to address unmet needs in dermatology.

Dermata Therapeutics (DRMA) Earnings & Revenues

Historic Earnings Reports

DRMA Stock 12 Month Forecast

Average Price Target

$10.00

▲(69.49% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","244":"$244","64.75":"$64.8","124.5":"$124.5","184.25":"$184.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,64.75,124.5,184.25,244],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2024","6":"Nov<br/>2024","9":"Mar<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.45,6.723076923076923,6.996153846153846,7.269230769230769,7.542307692307692,7.815384615384615,8.088461538461539,8.361538461538462,8.634615384615385,8.907692307692308,9.180769230769231,9.453846153846154,9.726923076923077,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.45,6.723076923076923,6.996153846153846,7.269230769230769,7.542307692307692,7.815384615384615,8.088461538461539,8.361538461538462,8.634615384615385,8.907692307692308,9.180769230769231,9.453846153846154,9.726923076923077,{"y":10,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.45,6.723076923076923,6.996153846153846,7.269230769230769,7.542307692307692,7.815384615384615,8.088461538461539,8.361538461538462,8.634615384615385,8.907692307692308,9.180769230769231,9.453846153846154,9.726923076923077,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":243.75,"date":1682899200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":190.5,"date":1690848000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.62,"date":1698796800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.12,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.88,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.8,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.25,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.7,"date":1733011200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":13.5,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":11.4,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":10,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":8.2,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.45,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >